TABLE 1.
Agreement between results obtained by the Vitek 2 yeast susceptibility test and CLSI BMD method, with data classified by Candida speciesa
| Species (nb) | Antifungal agent | Test system(s) | % EA | No. (%) of isolates with result
|
% CA | % Error
|
||||
|---|---|---|---|---|---|---|---|---|---|---|
| S | SDD | R | VME | ME | Minor | |||||
| C. albicans (36) | Fluconazole | Vitek 2 | 17 (47.2) | 8 (22.2) | 11 (30.6) | |||||
| Fluconazole | BMD | 91.6 | 17 (47.2) | 8 (22.2) | 11 (30.6) | 100.0 | 0.0 | 0.0 | 0.0 | |
| Voriconazole | Vitek 2 | 27 (75) | 4 (11.1) | 5 (13.9) | ||||||
| Voriconazole | BMD | 94.4 | 27 (75) | 3 (8.3) | 6 (16.7) | 97.2 | 0.0 | 0.0 | 2.8 | |
| C. glabrata (84)c | Fluconazole | Vitek 2 | 23 (27.4) | 15 (17.8) | 46 (54.8) | |||||
| Fluconazole | BMD | 100 | 24 (28.6) | 12 (14.3) | 48 (57.1) | 96.4 | 0.0 | 0.0 | 3.6 | |
| Voriconazole | Vitek 2 | 42 (50.0) | 13 (15.5) | 29 (34.5) | ||||||
| Voriconazole | BMD | 100 | 41 (48.8) | 13 (15.5) | 30 (35.7) | 97.6 | 0.0 | 0.0 | 2.4 | |
a
Abbreviations: EA, essential agreement; S, susceptible; SDD, susceptible, dose dependent; R, resistant; CA, categorical agreement; VME, very major error; ME, major error; minor, minor error.
b
n, no. of isolates tested.
c
Of all isolates tested (n = 86), two isolates had MICs not determinable with Vitek 2.